Literature DB >> 25511544

Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.

Yasuhiko Nakamura1, Toshiaki Kamei, Masahiro Shinagawa, Yuka Sakamoto, Ichiro Miwa.   

Abstract

Primary ovarian squamous cell carcinoma is uncommon, and the optimal treatment strategy for this disease has not yet been established. A 71-year-old woman diagnosed with FIGO stage IIb pure ovarian squamous cell carcinoma underwent cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin. After the second treatment course, a recurrent mass grew rapidly, and serum tumor maker levels increased. Monotherapy with weekly irinotecan was then instituted. This second-line chemotherapy was remarkably effective, and the patient subsequently underwent complete interval debulking surgery with a pathological complete response after the third treatment course. Weekly irinotecan is an effective choice for primary ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin.
© 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  carboplatin; irinotecan; ovarian cancer; paclitaxel; squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25511544     DOI: 10.1111/jog.12631

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin.

Authors:  Hiroyuki Yazawa; Tsuyoshi Hiraiwa; Fumihiro Ito; Keiya Fujimori
Journal:  Obstet Gynecol Sci       Date:  2017-10-17

2.  Pure primary ovarian squamous cell carcinoma: A case report and literature review.

Authors:  Yan Luo; Ce Bian
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.